Thrombosis · people with antiphospholipid antibodies and no history of thrombosis
1 finding from 1 review
Bleeding ‐ major (bleeding requiring transfusion) Length of · people with antiphospholipid antibodies and no history of thrombosis
ASA with LMWH showed no clear difference in bleeding ‐ major (bleeding requiring transfusion) Length of compared with placebo or IVIG (moderate certainty).
1 finding from 1 review
Bleeding ‐ other (bleeding during first trimester) Length of · people with antiphospholipid antibodies and no history of thrombosis
ASA with LMWH showed no clear difference in bleeding ‐ other (bleeding during first trimester) Length of compared with placebo or IVIG (moderate certainty).
1 finding from 1 review
Bleeding ‐ other (postpartum haemorrhage) Length of · people with antiphospholipid antibodies and no history of thrombosis
ASA with LMWH showed no clear difference in bleeding ‐ other (postpartum haemorrhage) Length of compared with placebo or IVIG (moderate certainty).
1 finding from 1 review
All‐cause mortality · people with antiphospholipid antibodies and no history of thrombosis
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Quality of life · people with antiphospholipid antibodies and no history of thrombosis
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Adverse events other than bleeding · people with antiphospholipid antibodies and no history of thrombosis
1 finding from 1 review
no estimate extracted
1 study · 3 participants
GRADE not reported
Thrombosis · people with antiphospholipid antibodies and no history of thrombosis
ASA showed no clear difference in thrombosis compared with placebo (low certainty).
1 finding from 1 review
Major bleeding · people with antiphospholipid antibodies and no history of thrombosis
1 finding from 1 review
Minor bleeding · people with antiphospholipid antibodies and no history of thrombosis
ASA showed no clear difference in bleeding ‐ minor compared with placebo (low certainty).
1 finding from 1 review
Deep vein thrombosis · prevention of venous thromboembolism in patients with lower‐limb immobilization
Low molecular weight heparin probably leads to lower deep venous thrombosis compared with no prophylaxis or placebo (moderate certainty).
1 finding from 1 review
Pulmonary embolism · prevention of venous thromboembolism in patients with lower‐limb immobilization
Low molecular weight heparin showed no clear difference in pulmonary embolism compared with no prophylaxis or placebo (low certainty).
1 finding from 1 review
Symptomatic venous thromboembolism · prevention of venous thromboembolism in patients with lower‐limb immobilization
Low molecular weight heparin may leads to lower symptomatic venous thromboembolism compared with no prophylaxis or placebo (low certainty).
1 finding from 1 review
Mortality due to pulmonary embolism · prevention of venous thromboembolism in patients with lower‐limb immobilization
1 finding from 1 review
Mortality due to other causes · prevention of venous thromboembolism in patients with lower‐limb immobilization
Low molecular weight heparin showed no clear difference in mortality due to other causes compared with no prophylaxis or placebo (low certainty).
1 finding from 1 review
Adverse outcomes · prevention of venous thromboembolism in patients with lower‐limb immobilization
Low molecular weight heparin showed no clear difference in adverse outcomes compared with no prophylaxis or placebo (low certainty).
1 finding from 1 review
All‐cause mortality, 30 days1 · patients of any age with AAA less than 30 mm in diameter
Metoprolol showed no clear difference in all‐cause mortality, 30 days1 compared with placebo (low certainty).
1 finding from 1 review
All cardiovascular death · patients of any age with AAA less than 30 mm in diameter
Metoprolol showed no clear difference in cardiovascular death, 30 days3 compared with placebo (low certainty).
2 findings from 1 review
AAA‐related death, 30 days4 · patients of any age with AAA less than 30 mm in diameter
Metoprolol showed no clear difference in AAA‐related death, 30 days4 compared with placebo (low certainty).
2 findings from 1 review
Nonfatal cardiovascular event, 30 days5 · patients of any age with AAA less than 30 mm in diameter
Metoprolol showed no clear difference in nonfatal cardiovascular event, 30 days5 compared with placebo (low certainty).
1 finding from 1 review